Joshua Richter, MD from John Theurer Cancer Center discusses next step for Phase 1 GBR 1342 studies and identifying the maximum tolerated dose to proceed to Phase 2 at the 2017 American Society of Hematology.
Next Step for Phase 1 GBR 1342 Studies – Identify the maximum tolerated dose to proceed to Phase 2
